Wednesday, June 10, 2026

pharma Β· Fibromyalgia Β· Primary Fibromyalgia Β· TNXP

Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding clinical programs β€” 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

200 Connell Dr, Berkeley Heights, New Jersey 07922, US HQ
2007 Founded
154 Employees
Public company Type
TNXP Β· NYSE Ticker
Company details
Status
Public
HQ
200 Connell Dr, Berkeley Heights, New Jersey 07922, US
Founded
2007
Employees
154
Programs
30
Drugs
10
Patents
86
Intelligence Β· Clinical Programs

Tonix Pharmaceuticals Holding projects

14 ClinicalTrials.gov programs sponsored by Tonix Pharmaceuticals Holding.

Tonix Pharmaceuticals Holding has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 2017-004466-98

    Tonix Pharmaceuticals Holding

    Pain, Face

    phase 1 small molecule completed

    1 trial
  2. Intranasal Oxytocin (IN-OXT)

    Tonix Pharmaceuticals Holding

    Vasopressin Deficiency

    phase 1 small molecule active

    1 trial
  3. SL TNX-102 2.4 mg at pH 3.5

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial
  4. SL TNX-102 at 2.4 mg

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial
  5. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  6. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Healthy Subjects (HS)

    phase 1 small molecule completed

    1 trial
  7. TNX-102 SL 5.6 mg

    Tonix Pharmaceuticals Holding

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  8. TNX-102 SL Tablet

    Tonix Pharmaceuticals Holding

    Pharmakokinetic

    phase 1 small molecule active

    1 trial
  9. TNX-102 SL Tablets at 2.8 mg

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial
  10. TNX-1500

    Tonix Pharmaceuticals Holding

    Phase 1 First-in-human Study Involving Healthy Subjects

    phase 1 small molecule completed

    1 trial
  11. TNX-201 35 mg

    Tonix Pharmaceuticals Holding

    Healthy

    phase 1 small molecule completed

    1 trial
  12. TNX-2110

    Tonix Pharmaceuticals Holding

    Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

    phase 1 mab terminated

    1 trial
  13. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy

    phase 1 small molecule completed

    1 trial
  14. Treatment A

    Tonix Pharmaceuticals Holding

    Healthy Adults

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Tonix Pharmaceuticals Holding have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.